Document Detail

Poly(ADP-ribosylation) and neoplastic transformation:Effect of PARP inhibitors.
MedLine Citation:
PMID:  22429135     Owner:  NLM     Status:  Publisher    
Poly(ADP-ribose) polymerases (PARPs) and poly(ADP-ribosylation) play essential roles in several biological processes, among which neoplastic transformation and telomere maintenance. In this paper, we review the poly(ADP-ribosylation) process together with the highly appealing use of PARP inhibitors for the treatment of cancer. In addition, we report our results concerning poly(ADP-ribosylation) in a cellular model system for neoplastic transformation developed in our laboratory. Here we show that PARP-1 and PARP-2 expression increases during neoplastic transformation, together with the basal levels of poly(ADP-ribosylation). Furthermore, we demonstrate a greater effect of the PARP inhibitor 3-aminobenzamide (3AB) on cellular viability in neoplastically transformed cells compared to normal fibroblasts and we show that prolonged 3AB administration to tumorigenic cells causes a decrease in telomere length. Taken together, our data support an active involvement of poly(ADP-ribosylation) in neoplastic transformation and telomere length maintenance and confirm the relevant role of poly(ADP-ribosylation) inhibition for the treatment of cancer.
Francesca Donà; Ilaria Chiodi; Cristina Belgiovine; Tatiana Raineri; Roberta Ricotti; Chiara Mondello; A Ivana Scovassi
Related Documents :
184325 - Studies on the interaction between coxsackievirus a9 and hela cells. i. plaque-forming ...
178485 - Growth inhibition of cells in cultures and of vaccinia virus infected hela cells by der...
8808335 - Transcriptional control of human papillomavirus type 18 oncogene expression in differen...
18842625 - Improved cell-penetrating peptide-pna conjugates for splicing redirection in hela cells...
20939035 - New biomarkers probing depth of cell senescence assessed by laser scanning cytometry.
20134195 - Disease-modifying immunotherapy for the management of autoimmune diabetes.
Publication Detail:
Type:  JOURNAL ARTICLE     Date:  2012-3-20
Journal Detail:
Title:  Current pharmaceutical biotechnology     Volume:  -     ISSN:  1873-4316     ISO Abbreviation:  -     Publication Date:  2012 Mar 
Date Detail:
Created Date:  2012-3-20     Completed Date:  -     Revised Date:  -    
Medline Journal Info:
Nlm Unique ID:  100960530     Medline TA:  Curr Pharm Biotechnol     Country:  -    
Other Details:
Languages:  ENG     Pagination:  -     Citation Subset:  -    
Istituto di Genetica Molecolare CNR, Via Abbiategrasso 207, 27100 Pavia, Italy.
Export Citation:
APA/MLA Format     Download EndNote     Download BibTex
MeSH Terms

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine

Previous Document:  Capsid Assembly as a Point of Intervention for Novel Anti-viral Therapeutics.
Next Document:  X-ray Crystallography as a tool for Mechanism-of-action Studies and Drug Discovery.